Buhl R, Banerji D. Int J Chron Obstruct Pulmon Dis. 2012;7:729–741.
On page 737 in the first paragraph of the “Safety” section, the final sentence “Serious adverse events occurred with a slightly lower frequency in the glycopyrronium treatment group (11%) compared with placebo (13%) and the tiotropium group (15%, Table 3).32,33” should read “Serious adverse events occurred with a slightly lower frequency in the glycopyrronium treatment group (10%) compared with placebo (13%) and the tiotropium group (15%, Table 3).32,33”
Table 3.
Most frequent adverse events (≥5% in any treatment group); SAEs occurring in ≥5 patients in any treatment group, deaths, discontinuations due to adverse events and electrocardiographic abnormalities; pooled data from GLOW1 and GLOW2. Adapted from D’Urzo A, Ferguson GT, van Noord JA, et al. Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. Respir Res. 2011;12:15632 and Kerwin E, Hébert J, Korenblat P, et al. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with moderate-to-severe COPD over 52 weeks: The GLOW2 study. Eur Respir J. July 26, 2012.33
| Glycopyrronium 50 μg od (n=1075) | Placebo (n=535) | Tiotropium 18 μg od (n=267) | |
|---|---|---|---|
| Patients with adverse events, n (%) | 719 (66.9) | 379 (70.8) | 198 (74.2) |
| COPD worsening | 302 (28.1) | 189 (35.3) | 90 (33.7) |
| Upper respiratory tract infection | 80 (7.4) | 53 (9.9) | 30 (11.2) |
| Nasopharyngitis | 75 (7.0) | 36 (6.7) | 21 (7.9) |
| Sinusitis | 28 (5.3) | 14 (5.2) | 10 (3.7) |
| Patients with SAEs, n (%) | 112 (10.4)a | 67 (12.5) | 41 (15.4)a |
| COPD worsening | 28 (2.6) | 27 (5.0) | 13 (4.9) |
| Pneumonia | 11 (1.0) | 9 (1.7) | 4 (1.5) |
| Atrial fibrillation | 7 (0.7) | 0 | 0 |
| Upper respiratory tract infection, bacterial | 3 (0.3) | 2 (0.4) | 0 |
| Deaths, n (%) | 6 (0.6)b | 5 (0.9) | 2 (0.7) |
| Discontinuation due to adverse event(s) | 74 (6.9) | 50 (9.3) | 20 (7.5) |
| Electrocardiographic abnormalities | |||
| Total notable | 45 (4.2) | 19 (3.6) | 14 (5.3) |
| QTcF > 500 msec | 2 (0.2) | 2 (0.4) | 0 |
| Increase from baseline 30–60 msec | 142 (13.2) | 60 (11.2) | 43 (16.2) |
| Increase from baseline > 60 msec | 7 (0.7) | 2 (0.4) | 0 |
Notes:
Includes patients that had events that occurred during the 30-day follow-up period
includes two patients who died during the 30-day follow-up period.
Abbreviations: SAEs, serious adverse events; GLOW, GLycopyrronium bromide in COPD airWays; od, once-daily; COPD, chronic obstructive pulmonary disease; QTcF, QT interval with Fridericia’s correction; msec, milliseconds.
On page 737 in the second paragraph of the “Safety” section, the first sentence “Discontinuations due to adverse events were 10% in the placebo group and 8% in the glycopyrronium and tiotropium groups.” should read “Discontinuations due to adverse events were 9% in the placebo group and 7% in the glycopyrronium and tiotropium groups.”
On page 737, Table 3 contains incorrect information. The corrected Table is set out below.